Search

Your search keyword '"Antibodies, Monoclonal pharmacology"' showing total 20,597 results

Search Constraints

Start Over You searched for: Descriptor "Antibodies, Monoclonal pharmacology" Remove constraint Descriptor: "Antibodies, Monoclonal pharmacology"
20,597 results on '"Antibodies, Monoclonal pharmacology"'

Search Results

1. Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness.

2. BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling.

3. Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.

4. Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.

5. Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody.

6. Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.

7. Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance.

8. Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [ 131 I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice.

9. Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD.

10. Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice.

11. Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.

12. A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A.

13. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition.

14. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].

15. Therapeutic efficacy of JEW-M449, an anti-TCTP monoclonal antibody, administered via the nasal route in a BALB/c mouse model of ovalbumin-induced acute asthma.

16. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects.

17. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment.

18. Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.

19. Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis.

20. The Impact of Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies with and without Apheresis on Platelet Aggregation in Familial Hypercholesterolemia.

21. Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.

22. IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms.

23. Mechanisms of resistance to daratumumab in patients with multiple myeloma.

24. The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects.

25. Supramolecular antibody-drug conjugates for combined antibody therapy and photothermal therapy targeting HER2-positive cancers.

26. Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.

27. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice.

28. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.

29. CD94 + natural killer cells potentiate pulmonary ischaemia-reperfusion injury.

30. A novel dual-epigenetic inhibitor enhances recombinant monoclonal antibody expression in CHO cells.

31. The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells.

32. Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity.

33. Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii.

34. A monoclonal antibody recognizing CD98 on human embryonic stem cells shows anti-tumor activity in hepatocellular carcinoma xenografts.

35. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.

36. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.

37. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma.

38. Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0.

39. Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.

40. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.

41. Evaluation of romosozumab's effects on bone marrow adiposity in postmenopausal osteoporotic women: results from the FRAME bone biopsy sub-study.

42. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension.

43. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone.

44. The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.

45. The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis.

46. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.

47. Fibrin drives thromboinflammation and neuropathology in COVID-19.

48. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

49. Selenium nanoparticles enhance the anti-tumor immune responses of anti-4-1BB antibody and alleviate the adverse effects on mice.

50. Therapeutic Potential of Antibody Targeting Neuronal Pentraxin Receptor in Esophageal Squamous Cell Carcinoma.

Catalog

Books, media, physical & digital resources